These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14042612)

  • 1. TREATMENT OF ADRENOCORTICAL CANCER WITH O,P'-DDD.
    NETTO AD; WAJCHENBERG BL; RAVAGLIA C; PEREIRA VG; SHNAIDER J; PUPO AA; CINTRA AB
    Ann Intern Med; 1963 Jul; 59():74-8. PubMed ID: 14042612
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and therapeutic observations in the adrenal cancer: a report on 7 patients treated with o,p'-DDD.
    MOLNAR GD; MATTOX VR; BAHN RC
    Cancer; 1963 Feb; 16():259-68. PubMed ID: 13935915
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy of adrenocortical cancer with o,p' DDD in two children.
    FISHER DA; PANOS TC; MELBY JC
    J Clin Endocrinol Metab; 1963 Feb; 23():218-21. PubMed ID: 24546774
    [No Abstract]   [Full Text] [Related]  

  • 4. ADRENOCORTICAL CARCINOMA TREATED WITH O,P' -DDD.
    MONTGOMERY DA; WELBOURN RB
    Br Med J; 1965 May; 1(5446):1356-8. PubMed ID: 14280300
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of o,p'-DDD therapy on plasma cholesterol in adrenal carcinoma.
    MOLNAR GD; NUNN SL; TAUXE WN
    Proc Staff Meet Mayo Clin; 1961 Nov; 36():618-20. PubMed ID: 14475247
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of adrenal virilism persisting unchanged after excision of bilateral adrenocortical adenoma.
    LETH PEDERSEN A
    Acta Endocrinol (Copenh); 1948; 1(2):153-70. PubMed ID: 18880936
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucocorticoid and mineralocorticoid pathways in two adrenocortical carcinomas: comparison of the effects of o,p'-dichlorodiphenyldichloroethane, aminoglutethimide and 2-p-aminophenyl-2-phenylethylamine in vitro.
    Touitou Y; Bogdan A; Auzeby A; Dommergues JP
    J Endocrinol; 1979 Jul; 82(1):87-94. PubMed ID: 479738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
    Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A
    J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Barzon L; Fallo F; Sonino N; Daniele O; Boscaro M
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1488-9. PubMed ID: 10199802
    [No Abstract]   [Full Text] [Related]  

  • 13. Virilizing adrenal tumor in a child suppressed with dexamethasone for three years. Effect of o,p'-DDD on serum and urinary androgens.
    Korth-Schutz S; Levine LS; Roth JA; Saenger P; New MI
    J Clin Endocrinol Metab; 1977 Mar; 44(3):433-9. PubMed ID: 138687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ADRENOCORTICAL HYPERANDROGENISM SYNDROMES].
    BRICAIRE H
    Cah Coll Med Hop Paris; 1964 Jun; 5():427-33. PubMed ID: 14157943
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical results of the use of mitotane for adrenocortical carcinoma.
    Kasperlik-Zaluska AA
    Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN.
    BLEDSOE T; ISLAND DP; NEY RL; LIDDLE GW
    J Clin Endocrinol Metab; 1964 Dec; 24():1303-11. PubMed ID: 14243174
    [No Abstract]   [Full Text] [Related]  

  • 17. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients.
    Garg MB; Sakoff JA; Ackland SP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2201-5. PubMed ID: 21719363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide.
    Scott RD
    Postgrad Med J; 1975 Jan; 51(591):35-7. PubMed ID: 1161676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.